Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2564380 | Pharmacology & Therapeutics | 2006 | 12 Pages |
Abstract
Mitoxantrone is approved by several health authorities for treatment of active forms of relapsing-remitting or secondary progressive multiple sclerosis (SPMS). This review provides an outline on relevant preclinical as well as clinical studies, places mitoxantrone in the context of other therapeutic approaches against multiple sclerosis (MS), and discusses relevant side effects. The current knowledge of the putative mechanisms of action of the compound is discussed.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Oliver Neuhaus, Bernd C. Kieseier, Hans-Peter Hartung,